Combination Treatment Approach Shows Promise for R/R Multiple Myeloma
نویسندگان
چکیده
منابع مشابه
Treatment of Multiple Myeloma
Les traitements classiques de myelome multiple et les schemas differents proposes ont ete mis en revue. La poly chimiotherapie de la maladie avec une com-binaison de cyclophosphamide, B.C.N.U. Alkeran, Perdnisone et Vincristine a donnee une meilleur Resultat ceci surtout dans les formes graves et rapidement progressive de la maladie. D'autres sehemas therapeutiques sont en cours.
متن کاملThalidomide and its derivatives: new promise for multiple myeloma.
BACKGROUND The combination of melphalan and prednisone has been accepted as standard treatment for multiple myeloma (MM) because most studies demonstrate only minimal survival benefit of combination chemotherapy regimens when compared with melphalan and prednisone. Despite modest gains with more intensive myeloablative regimens for certain subgroups, myeloma remains incurable. In 1999, investig...
متن کاملTreatment of Multiple Myeloma: Finding the Right Combination.
The treatment of multiple myeloma is evolving rapidly. The development of immunomodulatory drugs (IMiDs) in the late 1990s and proteasome inhibitors (PIs) in the first decade of this century has dramatically changed the outlook for patients, as we began seeing response rates never before imagined. Today the so-called novel agents are no longer novel but standard of care, and are being joined by...
متن کاملCurrent treatment for multiple myeloma.
In the past decade, we have witnessed dramatic changes in the treatment of multiple myeloma. Proteasome inhibitors such as bortezomib and carfilzomib target the ubiquitin pathway, resulting in cytotoxic injury due to disruption of protein degradation in myeloma cells. The immunomodulatory agents thalidomide, lenalidomide, and pomalidomide target myeloma cells through several mechanisms includin...
متن کاملMultiple Myeloma Update
This literature review presents the most recent developments in the management of multiple myeloma, which is characterized by the presence of abnormal plasma cells (myeloma cells) that accumulate into the bone marrow. Aspects related to pathophysiology, clinical manifestations, laboratory, study and treatment are described. These pieces of information are necessary to accomplish a better ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncology Times
سال: 2021
ISSN: 0276-2234
DOI: 10.1097/01.cot.0000735196.51054.e5